PfizerValnevas Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026
| VALN Stock | USD 4.55 0.11 2.36% |
About 53% of Valneva SE's investor base is interested to short. The analysis of the overall investor sentiment regarding Valneva SE ADR suggests that many traders are impartial. Valneva SE's investing sentiment overview a quick insight into current market opportunities from investing in Valneva SE ADR. Many technical investors use Valneva SE ADR stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Valneva |
On Wednesday, Pfizer Inc and Valneva SE announced that the participants of the Phase 3 VALOR trial have completed the primary vaccination series of Lyme disease vaccine candidate VLA15. Lyme disease is a bacterial infection that can be spread to humans by infected ticks. Participants will be monitored for the occurrence of Lyme disease cases until the end of the Lyme disease season in 2025. VLA15, the Lyme disease vaccine candidate we are co-developing wit
Read at finance.yahoo.com
 |
Valneva SE Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Valneva SE can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Valneva SE Fundamental Analysis
We analyze Valneva SE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Valneva SE using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Valneva SE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Valneva SE is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Valneva SE ADR Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Valneva SE stock to make a market-neutral strategy. Peer analysis of Valneva SE could also be used in its relative valuation, which is a method of valuing Valneva SE by comparing valuation metrics with similar companies.
Peers
Valneva SE Related Equities
| DMAC | DiaMedica Therapeutics | 3.49 | ||||
| DNTH | Dianthus Therapeutics | 1.03 | ||||
| VANI | Vivani Medical | 0.76 | ||||
| A | Agilent Technologies | 0.12 | ||||
| DNLI | Denali Therapeutics | 3.47 | ||||
| EQ | Equillium | 4.23 | ||||
| ME | 23Andme Holding | 5.67 |
Check out Valneva SE Hype Analysis, Valneva SE Correlation and Valneva SE Performance. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Valneva SE. If investors know Valneva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Valneva SE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.13) | Revenue Per Share 2.3 | Quarterly Revenue Growth 0.204 | Return On Assets (0.11) | Return On Equity (0.04) |
The market value of Valneva SE ADR is measured differently than its book value, which is the value of Valneva that is recorded on the company's balance sheet. Investors also form their own opinion of Valneva SE's value that differs from its market value or its book value, called intrinsic value, which is Valneva SE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Valneva SE's market value can be influenced by many factors that don't directly affect Valneva SE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Valneva SE's value and its price as these two are different measures arrived at by different means. Investors typically determine if Valneva SE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Valneva SE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.